Skip to Content
Søk Menu
Velkommen til lungekreft

Få de nyeste artiklene og MEDtalks om lungekreft

Siste nytt om lungekreft

The Nordic Countries Are Among the Best in the World – But the Lung Cancer Care Still Faces Key Challenges

  • / Odd Terje Brustugun
Bjørn H Grønberg

ASCO 2026: No Survival Benefit With Thoracic Radiotherapy in SCLC

/ Bjørn Henning Grønberg
ASCO26Lungekreft Play the Video
Saadettin Kılıçkap

ELCC 2026: Six-Year Outcomes of the EMPOWER-LUNG-1 Trial in Advanced NSCLC

/ Saadettin Kılıçkap
ELCC26Lungekreft Play the Video
Andreas Ravn Andersen

ELCC 2026: First-Line Immunotherapy in High PD-L1 Lung Cancer

/ Andreas Ravn Andersen
ELCC26Lungekreft Play the Video

Lung Cancer Highlights

Norwegian and Nordic Lung Cancer Insights – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft

Lung Cancer Insights: What’s New in the Field – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft

Lung Cancer Insights: What’s New in the Field

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft
Ahti Vehmanen

ELCC 2026: Integrating AI into Lung Cancer Practice

/ Ahti Vehmanen
ELCC26Lungekreft Play the Video

MEDtalks

Morten Borg

ELCC 2026: High Antidepressant Use Among Lung Cancer Patients

/ Morten Borg
ELCC26Lungekreft Play the Video
Giuseppe Luigi Banna

ELCC 2026: First-Line I-O Therapy Extends OS/PFS in Metastatic SCLC

/ Giuseppe Luigi Banna
ELCC26Lungekreft Play the Video
Milla Katajisto

ELCC 2026: Digital Tool for ECOG Assessment in Lung Cancer

/ Milla Katajisto
ELCC26Lungekreft Play the Video
Cecilie Mondrup Jacobsen

ELCC 2026: Blood-Based ML for Lung Cancer Prediction

/ Cecilie Mondrup Jacobsen
ELCC26Lungekreft Play the Video
Fred Hirsch

ELCC 2026: AI-Assisted PD-L1 Assessment in Lung Cancer

/ Fred Hirsch
ELCC26Lungekreft Play the Video
Martin Reck

ELCC 2026: Pembrolizumab + Chemo Improves EFS in Early-Stage NSCLC

/ Martin Reck
ELCC26Lungekreft Play the Video
Load more

Artikler

First-Line Lorlatinib in ALK-Positive NSCLC

/ Jon Alexander Lykkegaard Andersen
Lungekreft

First-Line Cemiplimab + Chemotherapy Improves Quality of Life and Delays Disease Deterioration in Advanced NSCLC Without Driver Mutations

/ Jan Andreasen
ELCC26Lungekreft

Lung Cancer Insights: What’s New in the Field – January Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft

Norwegian and Nordic Lung Cancer Insights – January Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft

Sustained Survival Benefit of Cemiplimab Plus Chemotherapy at 5 Years in Advanced NSCLC With PD-L1 ≥1%

/ Jan Andreasen
ImmunterapiLungekreft

Lung Cancer Insights: What’s New in the Field – December Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft

Back to top